DGAP-News: Sangui BioTech International Inc.: Wound therapeutic Granulox obtains another 18 years of patent protection for the entire European Union
(firmenpresse) - DGAP-News: Sangui BioTech International Inc. / Key word(s): Product
Launch/Miscellaneous
Sangui BioTech International Inc.: Wound therapeutic Granulox obtains
another 18 years of patent protection for the entire European Union
13.08.2013 / 16:30
---------------------------------------------------------------------
SanguiBioTech: Wound therapeutic Granulox obtains another 18 years of
patent protection for the entire European Union
Witten, Germany, August 13, 2013 - The European Patent Office has granted
SastoMed GmbH a European patent (EP 2550973, 'Wound Spray'). The patent
expands the existing protection of the wound therapeutic Granulox and
additionally safeguards its technology in terms of production as well as in
terms of application. In particular, the patent protection now applies to
all member countries of the European Union and was extended for another 18
years until the year 2031. SastoMed expects a positive decision with regard
to the corresponding application for an international patent.
'With the complementary European and international patents we expand the
reach of our protection well beyond the current core markets and we double
the period of validity as compared with the first patent', explains
SastoMed Managing Director Michael Sander. 'This move was carried out in
mutual understanding among all partners and within the framework of our
agreements. We are experiencing a strong interest in Granulox from numerous
different European countries. The territorial and temporal extension of the
patent protection is an excellent basis for a sustainable flow of revenues.
SastoMed GmbH and its shareholders SanderStrothmann GmbH and SanguiBioTech
GmbH will profit significantly from the enhanced revenue and earnings
potential. SanguiBioTech as licensor will also be able to capitalize on an
increase in royalty volume.'
SastoMed GmbH is a joint venture of SanguiBioTech GmbH (25%) and
SanderStrothmann GmbH (75%). It has been granted the global distribution
rights as licensee. SanguiBioTech GmbH receives royalties on all product
sales and is entitled to a share in all net profits corresponding to its
share in the company.
Sangui BioTech International, Inc. ('SGBI') is a holding company the shares
of which are being traded on the OTCQB marketplace (www.otcmarkets.com:
SGBI) and the OTC markets of Berlin and Hamburg-Hannover stock exchanges.
Its purpose is to provide financing and access to the capital markets for
the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.
For more information please contact:
Joachim Fleing
Phone: +49 (179) 7963472
Fax: +49 (2302) 915191
e-mail: fleing(at)sangui.de
End of financial news
---------------------------------------------------------------------
13.08.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
225638 13.08.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: EquityStory
" alt="First Majestic Reports Second Quarter Financial Results
Datum: 13.08.2013 - 16:30 Uhr
Sprache: Deutsch
News-ID 287271
Anzahl Zeichen: 3787
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 307 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Sangui BioTech International Inc.: Wound therapeutic Granulox obtains another 18 years of patent protection for the entire European Union"
steht unter der journalistisch-redaktionellen Verantwortung von
Sangui BioTech International Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
